Raymond James Forecasts Strong Price Appreciation for HLS Therapeutics (TSE:HLS) Stock

HLS Therapeutics (TSE:HLS) had its target price upped by equities researchers at Raymond James from C$4.00 to C$5.00 in a report issued on Friday,BayStreet.CA reports. Raymond James’ price objective would suggest a potential upside of 46.20% from the stock’s previous close.

Separately, Stifel Nicolaus dropped their target price on shares of HLS Therapeutics from C$3.75 to C$3.25 in a report on Tuesday, August 13th.

HLS Therapeutics Trading Up 3.3 %

Shares of HLS Therapeutics stock opened at C$3.42 on Friday. The business has a fifty day simple moving average of C$3.54 and a 200-day simple moving average of C$3.50. HLS Therapeutics has a fifty-two week low of C$3.00 and a fifty-two week high of C$5.48. The firm has a market cap of C$108.72 million, a price-to-earnings ratio of -3.39 and a beta of 1.07. The company has a quick ratio of 1.01, a current ratio of 2.02 and a debt-to-equity ratio of 100.44.

About HLS Therapeutics

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.